Prompt Antiviral Therapy Is Associated With Lower Risk of Cerebrovascular Accident Following Herpes Zoster Ophthalmicus.
Journal
American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
07
01
2021
revised:
15
06
2022
accepted:
22
06
2022
pubmed:
10
7
2022
medline:
28
9
2022
entrez:
9
7
2022
Statut:
ppublish
Résumé
To examine risk factors associated with cerebrovascular accident (CVA) following herpes zoster ophthalmicus (HZO). Retrospective cohort study. Review of medical records of all patients with HZO seen at the department of Ophthalmology, Auckland District Health Board, New Zealand, between January 1, 2006, and December 31, 2016. The main outcome measure was cerebrovascular accident within 12 months of diagnosis. A total of 869 patients diagnosed with HZO were included in the study. The median age at onset of HZO was 65.5 years (interquartile range [IQR] 52.9-75.4), and 52.5% (n=456) were male. Antiviral therapy was started in 765 participants (88.0%), not used in 95 (10.9%), and not documented in 9 participants (1.0%). Four hundred sixty-eight participants (54.9%) received prompt oral antiviral therapy (≤72 hours of rash onset). A CVA occurred in the 12 months following HZO in 14 patients (1.6%) and was most common in older patients, occurring in 2.5% aged ≥65 years, 0.7% aged 40-65 years, and 0.9% aged <40 years. Hazard of CVA was highest immediately following HZO, with median time to CVA of 2.3 months (IQR 0.8-5.9 months). Patients who received prompt acyclovir had a 76.2% lower hazard of CVA (0.9% vs 2.6%, P = .022) on multivariate analysis. Cerebrovascular accident occurs in a low proportion of individuals within 1 year following HZO. Antiviral treatment for HZO may reduce the risk of subsequent CVA when given within 72 hours of rash onset.
Identifiants
pubmed: 35809660
pii: S0002-9394(22)00256-2
doi: 10.1016/j.ajo.2022.06.020
pii:
doi:
Substances chimiques
Antiviral Agents
0
Acyclovir
X4HES1O11F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-220Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.